Wilder Thomas 4

What Happened

• Wilder Thomas, a director of Penumbra, was granted 589 restricted stock units (RSUs) on February 13, 2026. The RSUs were awarded at $0.00 per share (total value on grant = $0) as a compensation award (transaction code A). This is an issuance of equity-based compensation, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-13; Form 4 filed 2026-02-18 (timely filing given the Feb 16 federal holiday).
• Grant: 589 RSUs at $0.00 (award/acquisition).
• Vesting: 1/4 vests on each of Mar 31, Jun 30, Sep 30, and Dec 31, 2026, subject to continued service; any unvested RSUs will fully vest upon the Closing of the merger with Boston Scientific (per the Jan 14, 2026 merger agreement).
• A portion of the shares is subject to vesting; the filing notes the shares are held by the Thomas and Catharine Wilder Family Trust (dated Mar 31, 2006).
• Shares owned after the transaction are not specified in the filing.

Context

• RSUs are a common form of executive/director compensation and represent a promise to deliver shares in the future if vesting conditions are met; they do not necessarily reflect a personal buy or sell decision.
• The grant includes acceleration language tied to the announced merger with Boston Scientific, meaning unvested awards could vest sooner if the deal closes.